Procyon Advisors
ABBV icon

Procyon Advisors’s AbbVie ABBV Stock Holding History

Procyon Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.01M Buy
34,462
+2,070
+6% +$531K 0.38% 57
2026
Q2 		$8.15M Sell
32,392
-447
-1% -$96.2K 0.35% 63
2026
Q1 		$7.14M Buy
32,839
+87
+0.3% +$19.3K 0.35% 67
2025
Q4 		$7.48M Buy
32,752
+5,427
+20% +$1.24M 0.37% 65
2025
Q3 		$6.33M Buy
27,325
+1,933
+8% +$394K 0.37% 62
2025
Q2 		$4.71M Sell
25,392
-6,771
-21% -$1.26M 0.44% 53
2025
Q1 		$6.74M Buy
32,163
+4,302
+15% +$836K 0.41% 57
2024
Q4 		$4.95M Buy
27,861
+214
+0.8% +$39.3K 0.31% 72
2024
Q3 		$5.46M Sell
27,647
-1,227
-4% -$229K 0.37% 60
2024
Q2 		$4.95M Buy
28,874
+798
+3% +$132K 0.37% 60
2024
Q1 		$5.11M Sell
28,076
-2,112
-7% -$364K 0.4% 61
2023
Q4 		$4.68M Sell
30,188
-924
-3% -$135K 0.4% 56
2023
Q3 		$4.64M Buy
31,112
+2,811
+10% +$413K 0.48% 49
2023
Q2 		$3.81M Sell
28,301
-1,495
-5% -$219K 0.48% 48
2023
Q1 		$4.75M Buy
29,796
+563
+2% +$86.1K 0.79% 29
2022
Q4 		$4.72M Buy
29,233
+4,287
+17% +$657K 0.87% 25
2022
Q3 		$3.35M Sell
24,946
-3,210
-11% -$461K 0.82% 24
2022
Q2 		$4.31M Sell
28,156
-5,675
-17% -$867K 0.95% 22
2022
Q1 		$5.48M Buy
33,831
+1,898
+6% +$276K 1.13% 16
2021
Q4 		$4.32M Buy
31,933
+2,280
+8% +$269K 0.92% 21
2021
Q3 		$3.2M Buy
29,653
+1,920
+7% +$219K 0.82% 28
2021
Q2 		$3.12M Buy
27,733
+8,617
+45% +$970K 0.85% 29
2021
Q1 		$2.07M Buy
19,116
+238
+1% +$25.5K 0.92% 25
2020
Q4 		$2.02M Buy
18,878
+1,066
+6% +$102K 0.99% 23
2020
Q3 		$1.56M Buy
17,812
+12
+0.1% +$1.13K 0.87% 29
2020
Q2 		$1.75M Buy
17,800
+962
+6% +$84.7K 0.93% 25
2020
Q1 		$1.28M Buy
16,838
+2,753
+20% +$234K 0.85% 29
2019
Q4 		$1.25M Buy
+14,085
New +$1.17M 0.76% 33

Other funds holding ABBV

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Procyon Advisors's ABBV Position: Q3 2026 in Review

Procyon Advisors increased its AbbVie (ABBV) stake by 6.4% in Q3 2026, buying an estimated $531K and bringing the position to 34,462 shares worth $9.01M. The position accounts for 0.38% of the portfolio, ranked #57.

Procyon Advisors first reported a position in ABBV in Q4 2019 and has held it in 28 quarters since. 3,830 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Procyon Advisors held 34,462 shares of AbbVie worth $9.01M as of Q3 2026.
  • Procyon Advisors bought 2,070 AbbVie shares in Q3 2026, an estimated $531K.
  • AbbVie made up 0.38% of Procyon Advisors's portfolio in Q3 2026, its #57 holding.
  • Procyon Advisors first reported a position in AbbVie in Q4 2019 and has held it in 28 quarters since.
  • 3,830 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Procyon Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.